🔴 Cue Biopharma is trading 6.8% down in pre-market

Cue Biopharma is trading 6.8% lower at $29.28 pre-market; the immediate catalyst is uncertain.

• Positive Phase 2 CUE-221 results announced September 20 sparked a sharp pre-market rise; shares later fell, closing September 25 at $31.41.
• A supplied alert says Wall Street Zen downgraded shares to Strong Sell on Saturday, September 26; search results neither confirm the report nor establish a link to Monday’s decline.
• Broader futures are lower, with supplied index moves under 0.5%.